Brea C. Lipe, MD

Articles by Brea C. Lipe, MD

A panel of 4 experts on multiple myeloma seated at a long table

Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 28th 2023

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

Treatment Decision-Making in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 28th 2023

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 21st 2023

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 21st 2023

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 14th 2023

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Dosing Considerations for Bispecific Antibodies in MM

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 14th 2023

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

Recent Data on Bispecific Antibodies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 7th 2023

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.